MX
Live price temporarily unavailable.
Price history
Maxcyte Inc (MXCT) is a Health Care company. Latest news and coverage below.
IPO: July 30, 2021 · $13.00 offering · NASDAQ · View IPO details →
Maxcyte Inc revenue & net income history (FY2019–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $21.6M | $26.2M | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Growth (year over year) | — | +21.0% | +29.5% | +30.6% | −6.7% | −6.4% | −14.5% |
| Gross profit | $19.1M | $23.4M | $30.2M | $39.2M | $36.5M | $31.5M | $26.8M |
| Gross margin | 88.4% | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Operating income | −$12.4M | −$11.1M | −$18.2M | −$27.4M | −$48.3M | −$51.2M | −$51.9M |
| Operating margin | −57.4% | −42.3% | −53.7% | −61.8% | −117.0% | −132.5% | −157.1% |
| Net income | −$12.9M | −$11.8M | −$19.1M | −$23.6M | −$37.9M | −$41.1M | −$44.6M |
| Net margin | −59.6% | −45.2% | −56.3% | −53.3% | −91.8% | −106.3% | −135.1% |
| EPS (diluted) | −$0.23 | −$0.17 | −$0.21 | −$0.23 | −$0.37 | −$0.39 | −$0.42 |
| Balance sheet | |||||||
| Cash and equivalents | $15.2M | $18.8M | $47.8M | $11.1M | $46.5M | $27.9M | $20.1M |
| Total assets | — | $51.8M | $284.1M | $286.7M | $268.3M | $239.5M | $202.5M |
| Total liabilities | — | $18.6M | $21.2M | $32.7M | $36.1M | $33.2M | $31.0M |
| Shareholders' equity | $13.6M | $33.2M | $262.9M | $254.0M | $232.2M | $206.3M | $171.5M |
| Cash flow | |||||||
| Operating cash flow | −$8.80M | −$8.78M | −$10.7M | −$14.8M | −$21.7M | −$27.6M | −$34.4M |
| Capital expenditure | $1.27M | $2.07M | $3.83M | $18.5M | $3.70M | $1.65M | $1.77M |
| Free cash flow | −$10.1M | −$10.9M | −$14.5M | −$33.3M | −$25.4M | −$29.3M | −$36.2M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.16M | $8.69M | $10.4M | $8.51M | $6.83M | $7.30M | $9.65M | $7.27M |
| Growth (year over year) | +2.0% | −44.5% | −8.4% | −18.4% | −16.4% | −16.0% | −7.1% | −14.5% |
| Gross profit | $6.24M | $6.41M | $8.89M | $6.99M | $5.23M | $5.69M | $8.08M | $5.60M |
| Gross margin | 76.4% | 73.8% | 85.6% | 82.1% | 76.6% | 77.9% | 83.7% | 77.0% |
| Operating income | −$14.1M | −$12.9M | −$12.3M | −$14.2M | −$14.1M | −$11.2M | −$6.18M | −$10.2M |
| Operating margin | −172.1% | −148.4% | −118.3% | −167.2% | −207.2% | −153.8% | −64.1% | −140.7% |
| Net income | −$11.6M | −$10.6M | −$10.3M | −$12.4M | −$12.4M | −$9.60M | −$4.75M | −$8.87M |
| Net margin | −141.6% | −121.9% | −98.8% | −145.3% | −181.8% | −131.5% | −49.2% | −122.0% |
| EPS (diluted) | −$0.11 | −$0.10 | −$0.10 | −$0.12 | −$0.12 | −$0.08 | −$0.04 | −$0.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $37.0M | $27.9M | $23.4M | $15.2M | $13.0M | $20.1M | $14.6M | $15.0M |
| Total assets | $248.6M | $239.5M | $230.0M | $219.8M | $213.5M | $202.5M | $194.5M | $184.7M |
| Total liabilities | $35.3M | $33.2M | $30.5M | $29.0M | $33.2M | $31.0M | $26.6M | $25.9M |
| Shareholders' equity | $213.3M | $206.3M | $199.4M | $190.7M | $180.3M | $171.5M | $167.9M | $158.8M |
| Cash flow | ||||||||
| Operating cash flow | −$4.39M | −$7.82M | −$14.4M | −$9.85M | −$7.46M | −$2.69M | −$8.17M | −$4.66M |
| Capital expenditure | $406.0K | $147.0K | $653.0K | $584.0K | $300.0K | $231.0K | $72.0K | $62.0K |
| Free cash flow | −$4.80M | −$7.97M | −$15.1M | −$10.4M | −$7.76M | −$2.92M | −$8.24M | −$4.72M |
From Maxcyte Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Maxcyte Inc
- Headquarters
- Rockville, Maryland From SEC filings, Oct 2026
Recent News (2)
-
MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook TradingView
-
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International